Endocrine Abstracts

Background: Medullary thyroid carcinoma (MTC) is a rare disease accounting for 1-3% of all thyroid carcinomas. Unfortunately, most patients present with metastasized disease: 70% with cervical lymph node metastasis and 5-10% with distant metastasis. Survival strongly correlates with stage of disease at diagnosis, illustrating the need for early diagnosis. Calcitonin is a well-established tumour marker for MTC, but its use in the screening phase is limited by a high rate of fal...

Background: Patients with medullary thyroid carcinoma (MTC), a neuroendocrine tumour derived from the parafollicular C-cells, often present with metastasized disease. Survival strongly correlates with stage of disease at diagnosis, illustrating the need for early diagnosis. Calcitonin (CT), a well-established tumour marker for MTC, is limited by a high rate of false positives in the screening phase. Promising new markers for MTC are procalcitonin (PCT) and progastrin releasin...